Less Frequent Zoledronic Acid Not Linked to Increased Skeletal Events for Patients With Bone Metastases
January 8th 2017
Among patients with bone metastases due to breast cancer, prostate cancer, or multiple myeloma, those who used zoledronic acid every 12 weeks, compared with the standard dosing interval of every 4 weeks, did not experience an increased risk of skeletal-related events over 2 years.